A marijuana-focused news outlet recently spotlighted MJNA investment company AXIM® Biotechnologies and its upcoming trial of its cannabinoid-based gum for IBS.
Medical Marijuana, Inc. investment company AXIM® Biotechnologies and its cannabinoid-based gum were recently championed by MMJ Reporter. The leading marijuana-focused media outlet spotlighted AXIM® Biotechnologies’ trial of its CanChew Plus® CBD gum for the treatment of irritable bowel syndrome (IBS).
Describing the upcoming trial as “a landmark for… the medical cannabis industry,” the MMJ Reporter piece celebrated the efforts of AXIM® Biotechnologies what they could mean for those diagnosed with IBS, a condition with currently no valid treatment options.
What is IBS?
IBS, a chronic intestinal disorder that requires long term care, affects between 25 and 45 million people in the United States alone, and 15 percent of the worldwide population. The syndrome, also sometimes referred to as spastic colon, causes symptoms such as:
- Abdominal pain
- Diarrhea or constipation
AXIM® Biotechnologies IBS Trial
As explained in the piece by MMJ Reporter, AXIM® Biotechnologies is currently in Phase 2b of its study on IBS patients featuring its CanChew Plus® CBD gum. Each piece of the gum contains 50 mg of cannabidiol (CBD).
The MMJ Reporter article described the AXIM® trial as a “first of its kind,” and that it “highlights how far AXIM® Biotechnologies is far ahead in the clinical development programs.”
The study, being conducted by Renger Witkamp, Professor and Chair in Nutrition and Pharmacology at Wageningen University in the Netherlands, features 40 trial patients between the ages of 18 and 65 years that have been diagnosed with IBS. It is scheduled to begin in December.
Read the full article from MMJ Reporter.